According to early results published on Wednesday, Novavax Inc’s (NVAX.O) COVID-19 vaccine is efficient in eliciting an immune response against the Omicron variation, implying that the US drugmaker’s existing COVID-19 vaccine jobs can help tackle the new Omicron form.
The World Health Organization and European Union officials approved Novavax’s two-dose protein-based vaccination this week. L1N2T50VX Countries such as Indonesia and the Philippines have previously allowed it, but the United States has not.
The immune response to Omicron was further enhanced by obtaining an additional booster dosage of Novavax’s vaccine, according to Novavax. The information comes from Novavax’s ongoing research into the vaccine’s efficacy in teenagers and as a booster.
“We are encouraged those boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax’s president of research and development jobs.
Early research from Pfizer Inc. (PFE.N) and Moderna Inc. (MRNA.O), two other COVID-19 vaccine makers, has revealed that their products also boost immune responses to Omicron. People who have received an additional booster dose had higher resistance in all circumstances.
Novavax is working on an Omicron-specific vaccination, and the company stated on Wednesday that it plans to start producing doses of the variant-specific shot in January. As part of a deal to sell up to 200 million doses of vaccine to the EU’s 27 member states, the pharmaceutical jobs will begin sending vaccines in January.
In early 2022, the company will also begin shipments to COVAX, a WHO-managed vaccine distribution system that distributes COVID-19 injections to poorer countries and outsource more manpower jobs. Novavax and its partner, the Serum Institute of India, have committed to supply over 1.1 billion doses of Novavax’s vaccine to COVAX.